ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Ozanimod Did Not Appear to Lead to More Adverse Pregnancy Outcomes

ORLANDO — Women with inflammatory bowel disease or relapsing multiple sclerosis who became pregnant while taking the sphingosine-1-phosphate (S1P) receptor modulator ozanimod (Zeposia) did not

December 20, 2023

COVID-19 vaccine associated with reduced risk of cardiac and clot-related complications after SARS-CoV-2 infection

The risk of cardiac and clot-related complications following COVID-19 is substantially reduced in people who receive the COVID-19 vaccination compared with unvaccinated individuals, reports an

March 18, 2024

How Bedfont® is committing to their eco resolution this World Environment Day.

June 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.